Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

Archives of General Psychiatry
John W NewcomerGregg Selke

Abstract

Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Modified oral glucose tolerance tests were performed in schizophrenic patients (n = 48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n = 31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Significant time x treatment group interactions were detected for plasma glucose (F(12,222) = 4.89, P<.001) and insulin (F(12,171) = 2.10, P =.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapin...Continue Reading

Citations

Jun 30, 2007·Journal of Endocrinological Investigation·E ShiloahM J Rapoport
Nov 2, 2013·Pathology, Research and Practice·Mohamed M El-SeweidyRawia S Amin
Jul 3, 2009·Psychopharmacology·Montserrat VictorianoRenaud de Beaurepaire
Jan 1, 2008·Advances in Dual Diagnosis·Debbie RobsonPia Mauro
Jun 1, 2004·Acta Neuropsychiatrica·Pierre Chue, Raphael Cheung
Apr 13, 2005·Clinical Therapeutics·John W Newcomer
Dec 22, 2004·Journal of General Internal Medicine·Wildon R FarwellWilliam M Tierney
Oct 20, 2004·The Journal of Clinical Psychiatry·Oliver D HowesLyn S Pilowsky
May 17, 2007·Schizophrenia Bulletin·William S Stone, Larry J Seidman
Mar 4, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Gabriela BalfRoss A Baker
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Martha SajatovicMatthew A Fuller
Sep 23, 2009·Circulation·Satish R RajDan M Roden
Apr 23, 2011·Journal of Child and Adolescent Psychopharmacology·Mark L NorrisAndy Ni
Apr 11, 2003·Current Psychiatry Reports·Ming T TsuangStephen V Faraone
Jul 20, 2002·Current Psychiatry Reports·Jeremy A Sable, Dilip V Jeste
Jan 29, 2008·Current Psychiatry Reports·Andrea Fagiolini, K N Roy Chengappa
Feb 4, 2009·Current Psychiatry Reports·John O BrooksOlya Krasnykh
Mar 29, 2008·Internal and Emergency Medicine·Lucia CarulliMarco Bertolotti
Aug 12, 2009·The Australian and New Zealand Journal of Psychiatry·Swapna VermaLye Yin Poon
Jan 7, 2010·The Australian and New Zealand Journal of Psychiatry·Hung-Chuan LinHerng-Ching Lin
Jan 7, 2004·Journal of the American Medical Directors Association·Peter D FeldmanAlan Breier
Jul 19, 2013·Current Cardiovascular Risk Reports·Donna J LangRic M Procyshyn
Jul 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter J WeidenHarold E Lebovitz
Jun 4, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jimmi NielsenChristoph U Correll
Oct 16, 2002·Journal of Psychosomatic Research·Dan W Haupt, John W Newcomer
Mar 22, 2005·Psychopharmacology·G D CooperA J Goudie
Nov 13, 2002·Journal of Child and Adolescent Psychopharmacology·Ema Saito, Vivian Kafantaris
Oct 23, 2012·Journal of Child and Adolescent Psychopharmacology·Adam Philip Stern, Michael Long Trieu
May 2, 2003·Psychosomatics·Jennifer M LafayetteDavid C Henderson
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Lisa Catapano, David Castle
Sep 22, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Peter Herriot, Kamran Kheirani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Comprehensive Psychiatry
S MukherjeeP L Scapicchio
The Cochrane Database of Systematic Reviews
Graeme ToshMargueritte M White
Psychoneuroendocrinology
Thomas J HuberHinderk M Emrich
© 2022 Meta ULC. All rights reserved